Condition
Childhood Leukemia, Acute Lymphoblastic
Total Trials
5
Recruiting
4
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Recruiting4
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07152041Phase 3Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT06855810Phase 2Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06882057Phase 2Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06764238Phase 2Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06482281Active Not Recruiting
COVID-19 and Childhood Cancer
Showing all 5 trials